ESCMID Study Group for Non-traditional Antibacterial Therapy – ESGNTA

News & Activities

New ESCMID Study Group

ESGNTA is a newly formed ESCMID Study Group, which has started its activities in the field of non-traditional antibacterials including Bacteriophage antimicrobial phage and phage related products for therapy.

Objectives of ESGNTA


Activity plan:

  • Sponsor ECCMID sessions with focus on different aspects of phage therapy and non- traditional antimicrobials including:
    • Phage finding and characterisation,
    • Clinical phage microbiology,
    • Clinical outcomes and Clinical trails’ results and pitfalls.
    • Non-traditional antimicrobials as emerging tools for the treatment of infectious diseases
  • Organisation of workshop/meeting under ESCMID auspices and support on
    • Phage discovery and microbiology;
    • Production of phages and optimal carriers for clinical use;
    • Regulatory hurdles for the use of non-traditional antimicrobials in clinical settings.
  • Creation and Publication of SG phage therapy clinical cases database
  • Supporting collaboration of phage banks for clinical use


Publication strategy:

  1. Establishing an online registry of human phage use for infections worldwide (local and systemic application)
  2. Establishing a reference laboratory for phage biobank, testing, distribution, magistral preparation (cooperation with academic and research institutions and the ELIAVA institute in Georgia)
  3. Guidelines for emergency use of phages in human infections
  4. Guidelines on treatment with phage therapy for different site infections (e.g.  bone infections, implant-associated infections, infections in immune compromised hosts, etc.)